Table 1 Baseline patients characteristics (n=30)
From: Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
n | % | |
|---|---|---|
Gender: male/female | 16/14 | 53/47 |
Median age (range, in years) | 59 (31–80) | |
Primary melanoma | ||
SSM | 17 | 57 |
Nodular | 4 | 13 |
Uveal | 3 | 10 |
Unknown primary | 4 | 13 |
Others | 2 | 7 |
AJCC stage IV | ||
M1a | 1 | 3 |
M1b | 2 | 7 |
M1c | 27 | 90 |
>2 Metastatic sites | 22 | 73 |
Lung metastases | 18 | 60 |
Liver metastases | 19 | 63 |
Brain metastases | 10 | 33 |
LDH>N | 14 | 47 |
Previous chemotherapy | 28 | 93 |
⩾2 Lines of chemotherapy | 22 | 73 |
Performance Status (WHO) | ||
0–1 | 24 | 80 |
2–3 | 6 | 20 |
Median time from first metastasis (range, in months) | 15 (1–59) | |
